Pro Medicus (PMCUF) Stock Price, News & Analysis

Company Overview

Pro Medicus Limited is a global provider of advanced medical imaging and healthcare IT solutions, offering software and services that streamline diagnostic workflows for hospitals, imaging centers and teleradiology practices. The company’s flagship product, Visage 7, is a server-side, zero-footprint enterprise imaging platform that delivers rapid access to diagnostic-quality images across multiple modalities, including CT, MRI, PET, digital pathology and cardiology. By leveraging a cloud-native architecture and high-performance streaming technology, Pro Medicus enables healthcare providers to improve clinical collaboration, reduce turnaround times and optimize resource utilization.

In addition to its core imaging viewer, Pro Medicus offers a suite of complementary modules such as enterprise archive, advanced visualization and workflow orchestration tools. These solutions support radiologists, pathologists and clinicians in conducting complex multi-disciplinary reviews, multi-site reporting and interventional case planning. The company also provides implementation, training and ongoing support services, working closely with IT teams and clinical users to tailor deployments to each customer’s existing environment and regulatory requirements.

Founded in 1983 by Dr. Anthony F. Wood, Pro Medicus began as a locally focused developer of radiology information systems in Melbourne, Australia. Over the past four decades, the company has expanded its footprint through organic growth and strategic partnerships, establishing regional offices in North America, Europe and Asia-Pacific. Pro Medicus is recognized for its commitment to interoperability, integration with third-party PACS, RIS and electronic medical record platforms, and adherence to industry standards such as DICOM and HL7. This global presence has enabled the company to support large healthcare networks, academic medical centers and specialist imaging providers around the world.

Under the leadership of CEO Dr. Sam Hupert and founder Dr. Wood, Pro Medicus continues to invest in research and development, focusing on artificial intelligence, cloud orchestration and advanced visualization techniques. The executive team combines deep clinical imaging expertise with strategic technology vision, guiding the company’s efforts to address evolving market demands, regulatory changes and emerging opportunities in digital pathology and telehealth. With a strong balance of innovation and customer focus, Pro Medicus aims to deliver scalable, future-ready imaging solutions that enhance patient care and drive operational efficiencies.

Key Stats

• Today's Range: $210.00 to $211.40
• 50-Day Range: $154.15 to $214.95
• 52-Week Range: $80.09 to $216.34
• Volume: 103 shs
• Average Volume: 900 shs
• Market Capitalization: N/A
• P/E Ratio: 14,093.33
• Dividend Yield: 0.01%
• Price Target: N/A
• Consensus Rating: N/A

PMCUF Stock Analysis - Frequently Asked Questions

How have PMCUF shares performed this year?

Pro Medicus' stock was trading at $155.27 at the beginning of 2025. Since then, PMCUF stock has increased by 36.1% and is now trading at $211.40.

How do I buy shares of Pro Medicus?

Shares of PMCUF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 7/18/2025
• Next Earnings (Estimated): 8/12/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Health Information Services
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:PMCUF
• CIK: 2013003
• Web: www.promed.com.au
• Phone: 61 3 9429 8800
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 14,093.33
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A